Literature DB >> 17371810

Bis-acridines as lead antiparasitic agents: structure-activity analysis of a discrete compound library in vitro.

Conor R Caffrey1, Dietmar Steverding, Ryan K Swenerton, Ben Kelly, Deirdre Walshe, Anjan Debnath, Yuan-Min Zhou, Patricia S Doyle, Aaron T Fafarman, Julie A Zorn, Kirkwood M Land, Jessica Beauchene, Kimberly Schreiber, Heidrun Moll, Alicia Ponte-Sucre, Tanja Schirmeister, Ahilan Saravanamuthu, Alan H Fairlamb, Fred E Cohen, James H McKerrow, Jennifer L Weisman, Barnaby C H May.   

Abstract

Parasitic diseases are of enormous public health significance in developing countries-a situation compounded by the toxicity of and resistance to many current chemotherapeutics. We investigated a focused library of 18 structurally diverse bis-acridine compounds for in vitro bioactivity against seven protozoan and one helminth parasite species and compared the bioactivities and the cytotoxicities of these compounds toward various mammalian cell lines. Structure-activity relationships demonstrated the influence of both the bis-acridine linker structure and the terminal acridine heterocycle on potency and cytotoxicity. The bioactivity of polyamine-linked acridines required a minimum linker length of approximately 10 A. Increasing linker length resulted in bioactivity against most parasites but also cytotoxicity toward mammalian cells. N alkylation, but less so N acylation, of the polyamine linker ameliorated cytotoxicity while retaining bioactivity with 50% effective concentration (EC(50)) values similar to or better than those measured for standard drugs. Substitution of the polyamine for either an alkyl or a polyether linker maintained bioactivity and further alleviated cytotoxicity. Polyamine-linked compounds in which the terminal acridine heterocycle had been replaced with an aza-acridine also maintained acceptable therapeutic indices. The most potent compounds recorded low- to mid-nanomolar EC(50) values against Plasmodium falciparum and Trypanosoma brucei; otherwise, low-micromolar potencies were measured. Importantly, the bioactivity of the library was independent of P. falciparum resistance to chloroquine. Compound bioactivity was a function of neither the potential to bis-intercalate DNA nor the inhibition of trypanothione reductase, an important drug target in trypanosomatid parasites. Our approach illustrates the usefulness of screening focused compound libraries against multiple parasite targets. Some of the bis-acridines identified here may represent useful starting points for further lead optimization.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17371810      PMCID: PMC1891397          DOI: 10.1128/AAC.01418-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  38 in total

1.  Antimalarial 9-anilinoacridine compounds directed at hematin.

Authors:  Saranya Auparakkitanon; Wilai Noonpakdee; Raymond K Ralph; William A Denny; Prapon Wilairat
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

2.  Structure-function relationships in aminoquinolines: effect of amino and chloro groups on quinoline-hematin complex formation, inhibition of beta-hematin formation, and antiplasmodial activity.

Authors:  T J Egan; R Hunter; C H Kaschula; H M Marques; A Misplon; J Walden
Journal:  J Med Chem       Date:  2000-01-27       Impact factor: 7.446

3.  Potent inhibition of scrapie prion replication in cultured cells by bis-acridines.

Authors:  Barnaby C H May; Aaron T Fafarman; Septima B Hong; Michael Rogers; Leslie W Deady; Stanley B Prusiner; Fred E Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-07       Impact factor: 11.205

4.  Antimalarial in-vivo activity of bis(9-amino-6-chloro-2-methoxyacridines).

Authors:  S Girault; S Delarue; P Grellier; A Berecibar; L Maes; L Quirijnen; P Lemiere; M A Debreu-Fontaine; C Sergheraert
Journal:  J Pharm Pharmacol       Date:  2001-07       Impact factor: 3.765

Review 5.  Treatment perspectives for human African trypanosomiasis.

Authors:  Bernard Bouteille; Odile Oukem; Sylvie Bisser; Michel Dumas
Journal:  Fundam Clin Pharmacol       Date:  2003-04       Impact factor: 2.748

6.  In vitro effect of alkaloids on bloodstream forms of Trypanosoma brucei and T. congolense.

Authors:  K Merschjohann; F Sporer; D Steverding; M Wink
Journal:  Planta Med       Date:  2001-10       Impact factor: 3.352

7.  Two interacting binding sites for quinacrine derivatives in the active site of trypanothione reductase: a template for drug design.

Authors:  Ahilan Saravanamuthu; Tim J Vickers; Charles S Bond; Mark R Peterson; William N Hunter; Alan H Fairlamb
Journal:  J Biol Chem       Date:  2004-04-21       Impact factor: 5.157

8.  In vitro activities of 7-substituted 9-chloro and 9-amino-2-methoxyacridines and their bis- and tetra-acridine complexes against Leishmania infantum.

Authors:  Carole Di Giorgio; Florence Delmas; Nathalie Filloux; Maxime Robin; Laetitia Seferian; Nadine Azas; Monique Gasquet; Muriel Costa; Pierre Timon-David; Jean-Pierre Galy
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

9.  Design, synthesis, and biological properties of new bis(acridine-4-carboxamides) as anticancer agents.

Authors:  Ippolito Antonini; Paolo Polucci; Amelia Magnano; Barbara Gatto; Manlio Palumbo; Ernesto Menta; Nicoletta Pescalli; Sante Martelli
Journal:  J Med Chem       Date:  2003-07-03       Impact factor: 7.446

10.  Cytotoxicity of acridine compounds for Leishmania promastigotes in vitro.

Authors:  K A Werbovetz; E K Lehnert; T L Macdonald; R D Pearson
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

View more
  10 in total

1.  Two approaches to discovering and developing new drugs for Chagas disease.

Authors:  J H McKerrow; P S Doyle; J C Engel; L M Podust; S A Robertson; R Ferreira; T Saxton; M Arkin; I D Kerr; L S Brinen; C S Craik
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-07       Impact factor: 2.743

2.  A Machine Learning Strategy for Drug Discovery Identifies Anti-Schistosomal Small Molecules.

Authors:  Kimberley M Zorn; Shengxi Sun; Cecelia L McConnon; Kelley Ma; Eric K Chen; Daniel H Foil; Thomas R Lane; Lawrence J Liu; Nelly El-Sakkary; Danielle E Skinner; Sean Ekins; Conor R Caffrey
Journal:  ACS Infect Dis       Date:  2021-01-12       Impact factor: 5.084

3.  Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis.

Authors:  Deuan C Jones; Irene Hallyburton; Laste Stojanovski; Kevin D Read; Julie A Frearson; Alan H Fairlamb
Journal:  Biochem Pharmacol       Date:  2010-08-07       Impact factor: 5.858

4.  Development and validation of a luminescence-based, medium-throughput assay for drug screening in Schistosoma mansoni.

Authors:  Cristiana Lalli; Alessandra Guidi; Nadia Gennari; Sergio Altamura; Alberto Bresciani; Giovina Ruberti
Journal:  PLoS Negl Trop Dis       Date:  2015-01-30

5.  9-phenyl acridine photosensitizes A375 cells to UVA radiation.

Authors:  Surajit Hansda; Gargi Ghosh; Rita Ghosh
Journal:  Heliyon       Date:  2020-09-03

Review 6.  Acridine-Based Antimalarials-From the Very First Synthetic Antimalarial to Recent Developments.

Authors:  Mélanie Fonte; Natália Tassi; Paula Gomes; Cátia Teixeira
Journal:  Molecules       Date:  2021-01-24       Impact factor: 4.411

7.  Improved tricyclic inhibitors of trypanothione reductase by screening and chemical synthesis.

Authors:  John L Richardson; Isabelle R E Nett; Deuan C Jones; Mohamed H Abdille; Ian H Gilbert; Alan H Fairlamb
Journal:  ChemMedChem       Date:  2009-08       Impact factor: 3.466

8.  Developing bivalent ligands to target CUG triplet repeats, the causative agent of myotonic dystrophy type 1.

Authors:  Yuan Fu; Kali A Miller; Lien Nguyen; Amin Haghighat Jahromi; Long M Luu; Anne M Baranger; Steven C Zimmerman
Journal:  J Med Chem       Date:  2013-11-21       Impact factor: 7.446

9.  In vitro activity of salinomycin and monensin derivatives against Trypanosoma brucei.

Authors:  Dietmar Steverding; Michał Antoszczak; Adam Huczyński
Journal:  Parasit Vectors       Date:  2016-07-25       Impact factor: 3.876

10.  Targeted Tumor Therapy with Radiolabeled DNA Intercalator: A Possibility? Preclinical Investigations with 177Lu-Acridine.

Authors:  Subhajit Ghosh; Tapas Das; Shishu K Suman; Chandan Kumar; Haladhar D Sarma; Ashutosh Dash
Journal:  Biomed Res Int       Date:  2020-07-25       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.